Priovant Launches Phase 2b/3 Trial for Brepocitinib in Lichen Planopilaris, Targeting Rare Scarring Hair Loss Disorder
Key Insights
Priovant has initiated a Phase 2b/3 clinical trial for brepocitinib in lichen planopilaris (search) (LPP), a rare inflammatory scalp disorder affecting approximately 100,000 adults in the United States.
LPP causes irreversible scarring hair loss with no FDA-approved treatments available, representing a critical unmet medical need that experts describe as a "trichologic emergency."
This marks the fourth indication in brepocitinib's late-stage development program, with the dual JAK1 (search)/TYK2 (search) inhibitor already showing promise in dermatomyositis (search) and other autoimmune conditions.
Priovant Therapeutics (search) has launched a Phase 2b/3 clinical trial for brepocitinib in lichen planopilaris (search) (LPP), a devastating inflammatory scalp disorder that causes irreversible scarring hair loss in approximately 100,000 adults in the United States. The seamless Phase 2b/3 potentially registrational trial enrolled its first subjects in March 2026, marking a significant milestone for patients facing this debilitating condition with no FDA-approved treatment options.
Critical Unmet Medical Need
LPP represents what dermatologists consider a "trichologic emergency," according to Dr. Kristen Lo Sicco, Chief of the Skin and Cancer Unit at NYU Langone Health and Associate Professor of Dermatology at NYU Grossman School of Medicine. "Absent early diagnosis and aggressive intervention, patients experience rapid hair loss that is generally irreversible, leaves permanent scarring, and is often accompanied by erythema, scaling, pain, itching and burning sensations," Dr. Lo Sicco explained.
The disorder specifically targets the stem cell-rich bulge region of the hair follicle, the permanent portion responsible for hair growth, resulting in generally irreversible hair loss and permanent scarring. Beyond the cosmetic impact, LPP patients experience profound pain, burning, itching, and scaling sensations. The condition also increases the risk of comorbidities including other autoimmune diseases and skin cancers.
Expanding Development Program
This LPP program represents the fourth indication in brepocitinib's expanding late-stage development program, joining dermatomyositis (search) (DM), non-infectious uveitis (search) (NIU), and cutaneous sarcoidosis (search) (CS). The FDA recently granted Priority Review to brepocitinib's New Drug Application for dermatomyositis and assigned a PDUFA target action date in the third quarter of 2026.
"Expanding brepocitinib into lichen planopilaris (search) continues our strategy of developing brepocitinib in highly morbid orphan conditions with limited treatment options and distinctive mechanistic benefits of dual JAK1 (search)/TYK2 (search) inhibition," said Ben Zimmer, Priovant CEO. "Moreover, as we look ahead to our expected product launch in DM in September, we see LPP as a strategic fit into a multi-indication rheum-derm rare disease franchise anchored by DM, with overlapping prescriber bases and thought leaders."
Scientific Rationale and Evidence
The decision to advance brepocitinib into LPP development is supported by multiple lines of evidence, including strong mechanistic rationale and clinically meaningful results from an investigator-initiated placebo-controlled study of brepocitinib in LPP. Brepocitinib is a first-in-class, selective inhibitor of TYK2 (search) and JAK1 (search) that distinctively suppresses key cytokines linked to autoimmunity—including type I IFN, type II IFN, IL-6, IL-12 and IL-23—through a single, targeted, once-daily oral therapy.
Pipeline Progress
Priovant's broader development timeline includes topline Phase 3 data in non-infectious uveitis (search) and Phase 3 study initiation in cutaneous sarcoidosis (search) expected in the second half of 2026. The company recently generated positive Phase 3 data in dermatomyositis (search), with the New Drug Application currently under FDA review.
The advancement into LPP reflects Priovant's strategic focus on developing treatments for autoimmune diseases with high morbidity and limited treatment options, leveraging the unique dual inhibition mechanism of brepocitinib to address multiple rare and debilitating conditions.